Emerging Treatment Options for Acute Lymphoblastic Leukemia : Focus on CAR T-Cell Therapy
Copyright © 2018 by the National Comprehensive Cancer Network..
Acute lymphoblastic leukemia (ALL) comprises a heterogeneous group of diseases with different morphologic, cytogenetic, and molecular subgroups, some of which have significant therapeutic implications. It typically presents with an aggressive clinical course, and among adults, responds poorly to standard chemotherapy, and carries a high risk for relapse. Despite the significant progress made in inducing remission, frequent relapses remain a challenge. Novel drugs, such as potent later-generation tyrosine kinase inhibitors, antibody-drug conjugates, bispecific monoclonal antibodies, and chimeric antigen receptor (CAR) T-cell therapies, are being investigated in patients with ALL. This summary describes therapies currently approved for the treatment of patients with ALL, identifies emerging targeted immunotherapies for patients with ALL, and discusses adverse events and mechanisms of resistance.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2018 |
|---|---|
| Erschienen: |
2018 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:16 |
|---|---|
| Enthalten in: |
Journal of the National Comprehensive Cancer Network : JNCCN - 16(2018), 5S vom: 22. Mai, Seite 651-655 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Brown, Patrick A [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
4FR53SIF3A |
|---|
| Anmerkungen: |
Date Completed 21.10.2019 Date Revised 10.12.2019 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.6004/jnccn.2018.0048 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM284308129 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM284308129 | ||
| 003 | DE-627 | ||
| 005 | 20231225042920.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.6004/jnccn.2018.0048 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0947.xml |
| 035 | |a (DE-627)NLM284308129 | ||
| 035 | |a (NLM)29784748 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Brown, Patrick A |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Emerging Treatment Options for Acute Lymphoblastic Leukemia |b Focus on CAR T-Cell Therapy |
| 264 | 1 | |c 2018 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 21.10.2019 | ||
| 500 | |a Date Revised 10.12.2019 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2018 by the National Comprehensive Cancer Network. | ||
| 520 | |a Acute lymphoblastic leukemia (ALL) comprises a heterogeneous group of diseases with different morphologic, cytogenetic, and molecular subgroups, some of which have significant therapeutic implications. It typically presents with an aggressive clinical course, and among adults, responds poorly to standard chemotherapy, and carries a high risk for relapse. Despite the significant progress made in inducing remission, frequent relapses remain a challenge. Novel drugs, such as potent later-generation tyrosine kinase inhibitors, antibody-drug conjugates, bispecific monoclonal antibodies, and chimeric antigen receptor (CAR) T-cell therapies, are being investigated in patients with ALL. This summary describes therapies currently approved for the treatment of patients with ALL, identifies emerging targeted immunotherapies for patients with ALL, and discusses adverse events and mechanisms of resistance | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Antibodies, Bispecific |2 NLM | |
| 650 | 7 | |a Antibodies, Monoclonal, Humanized |2 NLM | |
| 650 | 7 | |a Antineoplastic Agents |2 NLM | |
| 650 | 7 | |a Receptors, Antigen, T-Cell |2 NLM | |
| 650 | 7 | |a blinatumomab |2 NLM | |
| 650 | 7 | |a 4FR53SIF3A |2 NLM | |
| 650 | 7 | |a Inotuzumab Ozogamicin |2 NLM | |
| 650 | 7 | |a P93RUU11P7 |2 NLM | |
| 700 | 1 | |a Shah, Bijal |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of the National Comprehensive Cancer Network : JNCCN |d 2003 |g 16(2018), 5S vom: 22. Mai, Seite 651-655 |w (DE-627)NLM156397676 |x 1540-1413 |7 nnns |
| 773 | 1 | 8 | |g volume:16 |g year:2018 |g number:5S |g day:22 |g month:05 |g pages:651-655 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.6004/jnccn.2018.0048 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 16 |j 2018 |e 5S |b 22 |c 05 |h 651-655 | ||